Download Full eBooks in PDF
Emerging Drugs And Targets For Alzheimer S Disease Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Emerging Drugs And Targets For Alzheimer S Disease book. This book definitely worth reading, it is an incredibly well-written.
Author : Ana Martínez
Publisher : Royal Society of Chemistry
Page : 343 pages
File Size : 49,8 Mb
Release : 2010
Category : Medical
ISBN : 9781849730631
This volume describes the discovery and development history of the most promising drugs now in development for combating Alzheimer's disease.
Author : Ana Martínez
Publisher : Unknown
Page : 128 pages
File Size : 51,8 Mb
Release : 2010
Category : Electronic
ISBN : OCLC:948030175
Author : Ana Martinez
Publisher : Royal Society of Chemistry
Page : 242 pages
File Size : 49,9 Mb
Release : 2010-05-07
Category : Medical
ISBN : 9781849731072
Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.
Author : Dileep Kumar, Prashant Tiwari
Publisher : Bentham Science Publishers
Page : 289 pages
File Size : 42,9 Mb
Release : 2023-12-29
Category : Medical
ISBN : 9789815136159
The book summarizes the role of multiple enzyme targets and strategies to design and develop novel drug candidates for Alzheimer’s disease (AD). It brings together researchers across the globe having varied scientific backgrounds and expertise in a single volume. The chapters highlight current information scientists have unraveled about the origin, pathogenesis and prevention of AD. The contributions consider both established and emerging drug targets viz. Tau proteins, TREM, and microglia. Topics covered in the book include multi-target anti-Alzheimer's agents, epigenetic modifications, and the role of specific proteins like TMP21 and Tau in AD. A section dedicated to pharmacological treatments discusses the significance of tubulin-modifying enzymes, memantine, and glutamate antagonists. Enzymatic targets for drug discovery are thoroughly examined, focusing on cholinesterase, secretases, and other enzymes. Additionally, the book explores innovative nano-carrier-based drug delivery methods, emphasizing the crucial role of nanotechnology in effective Alzheimer's treatment. The book aims to inform students and researchers in the field of neuroscience, medicine and pharmacology about current research and biochemical nuances of AD pathogenesis and enzymatic drug targeting strategies. Readership Students and researchers in the field of neuroscience, medicine and pharmacology.
Author : Salvatore Salomone
Publisher : Frontiers Media SA
Page : 277 pages
File Size : 41,8 Mb
Release : 2020-07-02
Category : Electronic
ISBN : 9782889638208
Author : Michael S. Wolfe
Publisher : Springer
Page : 202 pages
File Size : 52,6 Mb
Release : 2017-05-15
Category : Science
ISBN : 9783319594606
Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors
Author : Atta-ur-Rahman,Muhammad Iqbal Choudhary
Publisher : Elsevier
Page : 784 pages
File Size : 54,7 Mb
Release : 2015-06-27
Category : Science
ISBN : 9780128039601
Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
Author : Jeffrey Cummings,Jefferson Kinney,Howard Fillit
Publisher : Cambridge University Press
Page : 575 pages
File Size : 51,7 Mb
Release : 2022-03-31
Category : Business & Economics
ISBN : 9781108838665
Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Author : Dileep Kumar,Vaishali M. Patil,Dee Wu,Nanasaheb Thorat
Publisher : Springer Nature
Page : 388 pages
File Size : 47,5 Mb
Release : 2023-10-02
Category : Medical
ISBN : 9789819926572
This book explains the fundamental characteristics and biofunctionality of Alzheimer’s Disease drug targets and provides up-to-date information on the full range of their biomedical applications. An introductory section gives an overview of the recent developments related to drug targets identified and studied related to Alzheimer’s Disease and key developments from preclinical and clinical studies focusing on various molecular targets related to AD and dementia by subject experts all around the globe. Here, individual chapters address the progress and perspectives in human and non-human research, role of various biomarkers as an overview, advanced gene therapy, and novel compounds for therapeutic targets for Alzheimer’s disease. The book will be essential reading for graduate students, scientists, and engineers in any of the biomedical research fields in which efforts are being made to utilize novel drug targets and develop effective strategies for new drug targeting and delivery in Alzheimer’s disease treatment.
Author : Paul C. Guest
Publisher : Springer Nature
Page : 274 pages
File Size : 48,7 Mb
Release : 2021-03-16
Category : Science
ISBN : 9783030550356
Aging is an inevitable part of life, and is becoming a worldwide social, economic and health problem due to the fact that an increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders. New therapeutic approaches are still in need to decrease or slow the effects of such diseases in this aging society. Advances in ‘omic technologies such as genomics, transcriptomics, proteomics and metabolomics have significantly advanced our understanding of diseases in multiple medical areas. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan, which will in turn lead to new therapeutic strategies and drug development projects by the pharmaceutical industry. This new book presents a series of reviews describing studies which have resulted in the identification of potential new drug targets for age-related disorders. Much of this information has come from ‘omic comparisons of healthy and disease states or from testing the effects of potential new therapeutic approaches. Each chapter will be presented in the context of specific chronic diseases or different therapeutic strategies, providing important information on disease mechanisms related to the aging process. This book will be of interest to researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians, and major drug companies. With contributors from Australia, Brazil, Canada, France, Germany, India, Iran, Iraq, South Africa, South Korea, Thailand, Ukraine, United Kingdom, United States of America, Uruguay and Vietnam, this is a timely follow up to Guest’s previous book Reviews on New Drug Targets in Age-Related Disorders.
Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publisher : National Academies Press
Page : 107 pages
File Size : 44,5 Mb
Release : 2014-02-06
Category : Medical
ISBN : 9780309292498
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Author : Ana Martinez
Publisher : Royal Society of Chemistry
Page : 287 pages
File Size : 45,8 Mb
Release : 2010-05-07
Category : Medical
ISBN : 9781849731065
Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism is an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.
Author : Ana Martínez
Publisher : Royal Society of Chemistry
Page : 327 pages
File Size : 45,7 Mb
Release : 2010
Category : Medical
ISBN : 9781849730648
This volume describes the discovery and development history of promising drugs now in development for combating Alzheimer's disease.
Author : Paul C. Guest
Publisher : Springer Nature
Page : 340 pages
File Size : 48,7 Mb
Release : 2020-04-17
Category : Science
ISBN : 9783030426675
Aging is an inevitable part of life and is becoming a worldwide social, economic and health problem. This is mainly due to the fact that the increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders, such as type II diabetes mellitus, cardiovascular disorders, sarcopenia, and neurodegenerative conditions. New therapeutic approaches are still needed to decrease or slow the effects of such diseases. Advances in -omic technologies, such as genomics, transcriptomics, proteomics and metabolomics, have significantly advanced our understanding of disease in multiple medical areas, as the analysis of multiple molecular networks has simultaneously provided a more integrated view of disease pathways. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan. In turn, this will lead to new therapeutic strategies as well as drug development projects by the pharmaceutical industry. This book presents a series of reviews describing studies that have resulted in identification of new potential drug targets for age-related disorders. Much of this information has come from -omic comparisons of healthy and disease states or from testing the effects of new therapeutic approaches. Authored by experts from around the globe, each chapter is presented in the context of specific chronic diseases or therapeutic strategies. This book is designed for researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians and stakeholders in major drug companies.
Author : Atta -Ur Rahman
Publisher : Frontiers in Clinical Drug Res
Page : 282 pages
File Size : 50,8 Mb
Release : 2019-03-04
Category : Medical
ISBN : 981140190X
Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD), a disease that causes dementia, or loss of brain function. This disease affects parts of the brain that affect memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer's disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in the field of Alzheimer's disease research. The eighth volume of this series features chapters covering critical discussions on new therapies for AD. The reviews in this volume include: - Novel Molecular Targets of Tauopathy; Therapeutic and Diagnostic Applications - The Therapy of Alzheimer's Disease: Towards a New Generation of Drugs - Could Antibiotics Be Therapeutic Agents in Alzheimer's Disease? - Use of Antipsychotics in Patients with Alzheimer's Disease - Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease - Potential Biological Mechanisms with Prophylactic Action in Rapid Cognitive Impairment in Late-Onset Alzheimer's Disease
